
× ×ª×× × ×ª×¨×פ×
××רש×

| ××× ×× ×× × ×ספ××
|
|
| ×§×××¦× ×¤×¨××§×××××ת (ATC4)
|
C10AX Other lipid modifying agents
|
| ×ר××× ×¤×¢×× (ATC5)
|
Â
|
| צ×רת ×ת×
|
תת-×¢××¨× - S.C
|
| צ×רת ××× ××
|
ת×××¡× ×××רק×, SOLUTION FOR INJECTION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר××
|
| ×ת××××
|
Primary hypercholesterolaemia and mixed dyslipidaemiaPraluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:- in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.Established atherosclerotic cardiovascular diseasePraluent is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:- in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
|
| × ×ª×× × ×ס×
|
ת×ר×× ××××× ×ס×
- 11/01/2018
|
×××××ת ×ס×
- תר××¤× ×××××ת ×ר×ש×× ×¢'× ×¨××¤× ××××× ×× ××××× ××רת
|
×ת×××× ×ס×
| ×ת×××× |
ת×ר×× ××××× |
ת××× ×§××× × |
Class Effect |
××¦× ×××× |
×ס×ס ×××××ת
|
| ×. ×תר××¤× ×ª×× ×ª× ××× ××¢× ×©× ××× ×ת ×©× ××ר××¢×× ×§×¨××××סק××ר××× ×××××× ×¢× ×××× ×§×¨××××סק××ר×ת ××××¢× ×©××× ×××× ×©×¨×ר ××× ×× ×©××¥ ×××× ××ס××× ×× ×××××× ×ש××ש ××©× ×× ××¨× ××ער×× ×ער×× ×-LDL ש××× ××¢× 100 ×"×/×צ"×, ××ר×ת ××פ×× ×ר×× ×ס×××× ×× ×ש×××× ×¢× Ezetimibe, ×××©× ×××ש××× ×פ××ת. ×. ת×××ת ×××פ×× ×תר××¤× ×××¢×©× ××¤× ××¨×©× ×©× ×¨××¤× ××××× ×קר×××××××× ×× ×¨××¤× ××××× ×××פ×××× ×× ×¨××¤× ××××× ×× ××ר××××××.
|
30/01/2020
|
××פ×××× |
|
××פר×××ס×ר×××××, ××ס××פ××××× |
|
| 4. ××ר××ת ×ש×××ש ×תר××¤× ALIROCUMAB (Praluent) ×. ×תר××¤× ×ª×× ×ª× ××× ××¢× ×©× ××× ×ת ×©× ××ר××¢×× ×§×¨××××סק××ר××× ×××××× ×¢× ×××× ×§×¨××××סק××ר×ת ××××¢× ×©××× ×××× ×©×¨×ר ××× ×× ×©××¥ ×××× ××ס××× ×× ×××××× ×ש××ש ××©× ×× ××¨× ××ער×× ×ער×× ×-LDL ש××× ××¢× 130 ×"×/×צ"×, ××ר×ת ××פ×× ×ר×× ×ס×××× ×× ×ש×××× ×¢× Ezetimibe, ×××©× ×××ש××× ×פ××ת. ×. ת×××ת ×××פ×× ×תר××¤× ×××¢×©× ××¤× ××¨×©× ×©× ×¨××¤× ××××× ×קר×××××××× ×× ×¨××¤× ××××× ×××פ××××.
|
1/01/2018
|
××פ×××× |
|
××פר×××ס×ר×××××, ××ס××פ××××× |
|
| ×. ×תר××¤× ×ª×× ×ª× ××× ××¢× ×©× ××× ×ת ×©× ××ר××¢×× ×§×¨××××סק××ר××× ×××××× ×¢× ×××× ×§×¨××××סק××ר×ת ××××¢× ×©××× ××¢×ר ×××× ×©×¨×ר ××× ×× ×©××¥ ×××× ××ס××× ×× ×××××× ×ער×× ×-LDL ש××× ××¢× 100 ×"×/×צ"×, ××ר×ת ××פ×× ×ר×× ×ס×××× ×× ×ש×××× ×¢× Ezetimibe, ×××©× ×××ש××× ×פ××ת. ×. ת×××ת ×××פ×× ×תר××¤× ×××¢×©× ××¤× ××¨×©× ×©× ×¨××¤× ××××× ×קר×××××××× ×× ×¨××¤× ××××× ×××פ×××× ×× ×¨××¤× ××××× ×× ××ר××××××.
|
01/02/2023
|
××פ××××
|
EVOLOCUMAB, ALIROCUMAB
|
××פר×××ס×ר×××××, ××ס××פ××××× |
|
|
ש×××ש ×ס×
-
|
×ס×רת ××××× ×ס×
- ×. ×תר××¤× ×ª×× ×ª× ××× ××¢× ×©× ××× ×ת ×©× ××ר××¢×× ×§×¨××××סק××ר××× ×××××× ×¢× ×××× ×§×¨××××סק××ר×ת ××××¢× ×©××× ××¢×ר ×××× ×©×¨×ר ××× ×× ×©××¥ ×××× ××ס××× ×× ×××××× ×ער×× ×-LDL ש××× ××¢× 100 ×"×/×צ"×, ××ר×ת ××פ×× ×ר×× ×ס×××× ×× ×ש×××× ×¢× Ezetimibe, ×××©× ×××ש××× ×פ××ת.
- ×. ת×××ת ×××פ×× ×תר××¤× ×××¢×©× ××¤× ××¨×©× ×©× ×¨××¤× ××××× ×קר×××××××× ×× ×¨××¤× ××××× ×××פ×××× ×× ×¨××¤× ××××× ×× ××ר××××××.
|
|
| ×¢××× ×ר××¤× ××××ר×ת ××¢×××
|
Â
Â
|
| ××פ×ש ×××ר××
|
×××ר×× ×-PubMed
|
| ××××¢ ×רשת
|
RxList WebMD Drugs.com
|
| ×©× ×צר×
|
SANOFI-AVENTIS GROUPE, FRANCE
|
| ×©× ××¢× ×ר×ש××
|
SANOFI - AVENTIS ISRAEL LTD
|
| ר×ש×××
|
ת×ר×× ××ש×: 8/2015. ר×ש××× ×ת×ר××:
|
| ת×ר×× ×¢×××× ××ר××
|
24/05/2023
|
ת××× ×ª ×ר×××
ת×ר×× ×¢××××: 24/05/2023
SANOFI
פר××××× × - Praluent
true
השינוי האחרון נעשה בֹ־25 באוגוסט 2024 ב־01:04